Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

13462156

Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

Home > Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

Overview

This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Key Inclusion Criteria

For a patient to be eligible for participation in this study, all of the following criteria must apply.

Age at least 18 years
Laboratory confirmed diagnosis of infection with SARS-CoV-2
Admitted to an acute care facility for the treatment of COVID-19 complications
Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease
Informed consent provided by the patient or healthcare proxy

Learn More

To learn more, visit ClinicalTrials.Gov

Study Type

Expanded Access

Sponsor(s)

Mayo Clinic

Contact Us

For more information about this study, please contact Clinical Research at

864-560-6812